Telix Pharmaceuticals Limited
TLPPF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $8,015 | $3,223 | $2,150 | $2,205 |
| - Cash | $710 | $123 | $116 | $22 |
| + Debt | $581 | $17 | $10 | $3 |
| Enterprise Value | $7,886 | $3,117 | $2,045 | $2,186 |
| Revenue | $783 | $503 | $160 | $8 |
| % Growth | 55.8% | 213.9% | 2,007.6% | – |
| Gross Profit | $510 | $314 | $29 | -$30 |
| % Margin | 65.1% | 62.6% | 18.3% | -391.9% |
| EBITDA | $98 | $23 | -$93 | -$70 |
| % Margin | 12.5% | 4.6% | -58% | -922.5% |
| Net Income | $50 | $5 | -$104 | -$81 |
| % Margin | 6.4% | 1% | -65% | -1,059.9% |
| EPS Diluted | 0.14 | 0.016 | -0.34 | -0.29 |
| % Growth | 769.6% | 104.7% | -17.2% | – |
| Operating Cash Flow | $43 | $24 | -$64 | -$59 |
| Capital Expenditures | -$34 | -$11 | -$14 | -$1 |
| Free Cash Flow | $9 | $13 | -$78 | -$61 |